Companies working on therapeutic peptides and proteins are constantly looking for methods of long-term delivery. InfiMed Therapeutics Inc. believes that its Improved Formulation Entity (IFE) no burst technology may offer such a platform. Likewise, Human Genome Sciences Inc. believes it has found a platform technology for formulation of long-circulating proteins and peptides through last week's acquisition of Principia Pharmaceutical Corp.

InfiMed was to announce today that its Infitropin sustained release human growth hormone (hGH) was 25 percent more effective in stimulating growth in rats than